<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78757">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01673646</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230C1202</org_study_id>
    <nct_id>NCT01673646</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pasireotide LAR in Japanese Patients With Acromegaly or Pituitary Gigantism</brief_title>
  <official_title>A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in
      Japanese patients with active acromegaly or pituitary gigantism. Primary objective is to
      assess the total-group efficacy of pasireotide LAR on the reduction of mean GH levels to &lt;
      2.5 µg/L and the normalization of IGF-1 at 3 months of study treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Growth Hormone (GH) and  glucagon-like peptide-1 (IGF-1)</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the total-group efficacy of pasireotide LAR on the reduction of mean GH levels to &lt; 2.5 µg/L and the normalization of IGF-1 at 3 months of study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GH and IGF-1</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effect of each starting dose pasireotide LAR on the reduction of mean GH levels to &lt; 2.5 µg/L and the normalization of IGF-1 at 3 months of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics</measure>
    <time_frame>predose, day2, day15, day22 and every 28days up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess Ctrough, Cmax and accumulation ratio of pasireotide LAR 20 mg, 40 mg and 60 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events as a Measure of safety and tolerability</measure>
    <time_frame>every 28days up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the tolerability and safety profile of pasireotide LAR at 3 months and during and after the 24- month study treatment using the National Cancer Institute-Common Toxicology Criteria (NCI-CTC) grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GH</measure>
    <time_frame>Baeline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 motnhs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effect of pasireotide LAR on the reduction of mean GH levels to &lt; 2.5 µg/L at 3, 6, 9, 12, 18 and 24 months of study treatment and the change of mean GH level from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1</measure>
    <time_frame>3 months, 6 months, 9 months, 12 months, 18 months and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effect of pasireotide LAR on the normalization of IGF-1 at 3, 6, 9, 12, 18, 24 months of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor volume</measure>
    <time_frame>Baseline, 6 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effect of pasireotide LAR on the change of tumor volume at 6and 12 months of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of clinical signs from baseline</measure>
    <time_frame>Baseline, every 3months up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical signs include ring size, headache, fatigue, perspiration, paresthesias, osteoarthralgia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolactin (PRL)</measure>
    <time_frame>Baseline, every 3 months up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effect of pasireotide LAR on the change of PRL level from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetic/Pharmacodynamic</measure>
    <time_frame>Day1, Day2, Day15, Day22, every 28days up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the relationship between pasireotide plasma concentration and GH/IGF-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GH and IGF-1</measure>
    <time_frame>6months, 9 months, 12 months 18 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the total-group efficacy of pasireotide LAR on the reduction of mean GH levels to &lt; 2.5 µg/L and the normalization of IGF-1 at 6, 9, 12, 18, 24 months of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acromegaly, Pituitary Gigantism</condition>
  <arm_group>
    <arm_group_label>SOM230LAR 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 enrolled patients will be randomized to 20mg pasireotide LAR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOM230LAR 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 enrolled patients will be randomized to 40mg pasireotide LAR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOM230LAR 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 enrolled patients will be randomized to 60mg pasireotide LAR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOM230LAR</intervention_name>
    <description>Intramuscular administration of pasireotide LAR will be repeated every month (1 month = 28 days) for 12 months in core phase. It is permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 &gt; ULN. In the event of any problem with tolerability, it is permitted to reduce the next lower dosage level at any time.</description>
    <arm_group_label>SOM230LAR 20mg</arm_group_label>
    <arm_group_label>SOM230LAR 40mg</arm_group_label>
    <arm_group_label>SOM230LAR 60mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with medication naïve acromegaly or pituitary gigantism

          -  Patients with inadequately controlled acromegaly or pituitary gigantism

        Exclusion Criteria:

          -  Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1c &gt;8%

          -  Patients who have congestive heart failure (NYHA Class III or IV), unstable angina,
             sustained ventricular tachycardia, ventricular fibrillation, clinically significant
             bradycardia, advanced heart block or a history of acute myocardial infarction within
             the six months preceding enrollment

          -  Patients with risk factors for torsade de pointes, i.e. patients with a baseline QTcF
             &gt; 470 ms, hypokalemia, hypomagnesemia, hypocalcemia, family history of long QT
             syndrome, or patients receiving a concomitant medication known to prolong QT interval
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba-city</city>
        <state>Chiba</state>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yoshida-gun</city>
        <state>Fukui</state>
        <zip>+8910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>807-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukushima-city</city>
        <state>Fukushima</state>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi-city</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morioka-city</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kita-gun</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kagoshima-city</city>
        <state>Kagoshima</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isehara-city</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>211-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>612-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8527</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yamagata</city>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>August 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SOM230, Pasireotide, acromegaly, Phase II</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Gigantism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
